Evidence map›Paper›PMID 41002294›Full record

ArticleAnalytical chemistry2025

A Flexible End-to-End Automated Sample Preparation Workflow Enables Standardized and Scalable Bottom-up Proteomics.

Sandra Schär, Luca Räss, Liliana Malinovska, Simonas Savickas, Francesca Cavallo, Christopher Below, Marco Tognetti, Polina Shichkova, Benoit Gourdet, Gonzalo Robles and 6 more

Abstract read
In one paragraph

Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sandra SchärBiognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland.ORCID 0009-0004-0870-451X
Luca RässBiognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland.
Liliana MalinovskaBiognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland.
Simonas SavickasBiognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland.
Francesca CavalloSygnature Discovery, Pennyfoot St, Nottingham NG1 1GR, U.K.
Christopher BelowBiognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland.
Marco TognettiBiognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland.ORCID 0000-0002-2379-1525
Polina ShichkovaBiognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland.ORCID 0000-0002-2574-1732
Benoit GourdetSygnature Discovery, Pennyfoot St, Nottingham NG1 1GR, U.K.
Gonzalo RoblesSygnature Discovery, Pennyfoot St, Nottingham NG1 1GR, U.K.
Leo IuSygnature Discovery, Pennyfoot St, Nottingham NG1 1GR, U.K.
Jakob VowinckelBiognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland.
Yuehan FengBiognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland.
Roland HjerpeSygnature Discovery, Pennyfoot St, Nottingham NG1 1GR, U.K.
Roland BrudererBiognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland.ORCID 0000-0002-1049-5524
Lukas ReiterBiognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland.ORCID 0000-0001-5751-3139

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bottom-up proteomics holds significant promise for clinical applications due to its high sensitivity and precision but is limited by labor-intensive, low-throughput sample preparation methods. Advanced automation is essential to enhance throughput, reproducibility, and accuracy and to allow standardization to make bottom-up proteomics amenable to large-scale studies. We developed a fully integrated, automated sample preparation platform that covers the entire process from biological sample input to mass-spectrometry-ready peptide output and can be applied to a multitude of biological samples. With this end-to-end solution, we achieved high intra- and interplate reproducibility, as well as longitudinal consistency, resulting in precise and reproducible workflows. We showed that our automated workflow surpasses established manual and semiautomated workflows, while improving time efficiency. Finally, we demonstrated the suitability of our automated sample preparation platform for drug development by performing high-content compound characterization for targeted protein degradation, where high throughput and quantitative accuracy are indispensable. For this, we coupled application-specific workflows to perform proteome profiling and confirm target degradation by precise protein quantification. Overall, our results highlight the selective degradation of specific proteins of interest for ten selected compounds across two cell lines. Thus, the automated sample preparation platform facilitates rapid adaptation to emerging developments in proteomics sample preparation, combining standardization, flexibility, and high-throughput capabilities to drive significant advancements in clinical assays and proteomics research.

Indexed as

ProteomicsAutomationHumansProteomeWorkflowProteome

Identifiers

PMID41002294
PMCPMC12529477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.